Royce & Associates »

Black Diamond Therapeutics shares owned by Royce & Associates

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by Royce & Associates from 13F filings

Historical chart of Royce & Associates investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by Royce & Associates consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by Royce & Associates

Quarter filed Position value Share count Share price at filing
2026-03-31 $36k 17k 2.13

More positions owned by Royce & Associates

Arcosa (ACA)
Quaker Chemical Corporation (KWR)
John Bean Technologies Corporation (JBTM)
ESCO Technologies (ESE)
MKS Instruments (MKSI)
Assured Guaranty (AGO)
Esab Corporation (ESAB)
SEI Investments Company (SEIC)
Intl Gnrl Insurance Hldngs L SHS (IGIC)
Ufp Industries (UFPI)
Lci Industries (LCII)
Inter Parfums (IPAR)
Exponent (EXPO)
Littelfuse (LFUS)
Cirrus Logic (CRUS)

View all positions for Royce & Associates

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
NEA Management Company
Acadian Asset Management
Vanguard Group
Dimensional Fund Advisors
Marshall Wace
BlackRock
Connor, Clark & Lunn Investment Management
Siren
Arrowstreet Capital, Limited Partnership
Renaissance Technologies
Mackenzie Financial
Goldman Sachs Group
Citadel Advisors
UBS Group

View all funds holding Black Diamond Therapeutics